Marisa Wexler, MS,  senior science writer—

Caring for children with multiple sclerosis (MS) can affect the mental health of their mothers over the long term, a study has found. The study, “Increased mental health care use by mothers of children with multiple sclerosis,” was published in the journal Neurology. People with…

The National Institute for Health Care and Excellence (NICE) in the U.K. issued its final decision, approving the inclusion of Plegridy (peginterferon beta-1a) to treat relapsing-remitting multiple sclerosis (RRMS) in England within the National Health Service (NHS). This decision follows a cost-effectiveness review done in May 2018,…

Genetic variations that increase body mass index (BMI) in childhood are associated with a higher risk of multiple sclerosis (MS) regardless of a person’s vitamin D levels, a study found. The study, “BMI and low vitamin D are causal factors for multiple sclerosis,” was published in…

People with multiple sclerosis (MS) who complete training through a method called the modified Story Memory Technique (mSMT) show a decrease in brain activity after training, which could indicate more efficient brain processing, a recent study shows. The study, “Brain activation patterns associated with paragraph…

Ocrevus (ocrelizumab) has been approved in Scotland as a treatment for early, inflammatory primary progressive multiple sclerosis (PPMS). The Scottish Medicines Consortium (SMC) has advised that Ocrevus can be prescribed by the National Health Service (NHS) for people with PPMS who have had symptoms for less than 15…

The first participant has been dosed in the Phase 2 REPAIR-MS clinical trial examining the effects of CNM-Au8, Clene Nanomedicine‘s investigational remyelinating therapy, on brain metabolism in people with multiple sclerosis (MS), the company announced. In MS, the immune system attacks myelin, the protective sheath that surrounds…

Anavex Life Sciences has received a U.S. patent covering the use of Anavex 2-73 (blarcamesine) for the treatment of several neurodegenerative and neurodevelopmental conditions, including multiple sclerosis (MS) and Rett syndrome. Issued by the U.S. Patent and Trademark Office, the new patent (no. 10,507,196) covers…

Gabapentinoids — a class of therapies sometimes used off-label to help control pain in people with multiple sclerosis (MS) — can increase the risk of serious breathing problems, particularly for those who have risk factors like poorer lung function or use opioid pain medicines, according to a warning…

Measuring the speed of signals sent to the brain by nerves in the eye could help assess if remyelination is taking place, a study in cats suggests. Such measurements could be useful in evaluating multiple sclerosis (MS) treatments aiming to repair myelin in clinical trials — of particular interest…

A grant awarded recently by the National Institutes of Health (NIH) will fund research to explore how brain changes in multiple sclerosis (MS) patients affect mobility. The five-year grant (1R01NS109023-01A1), totaling $3.5 million, was awarded by the National Institute of Neurological Disorders and Stroke, part of…

Small changes in daily activities, like sitting less and walking more, may be healthful for people with multiple sclerosis (MS) without the challenges of formal exercise. A new study, “Management of multiple sclerosis symptoms through reductions in sedentary behaviour: protocol for a feasibility study,” published in BMJ…

MetP Pharma‘s patent application for a new method to treat demyelinating and neuroinflammatory diseases, including multiple sclerosis (MS), has been approved by the United States Patent and Trademark Office (USPTO). The patent, titled “Treatment of Demyelinating Diseases” (U.S. Appl. No. 16/506,830), is valid until 2039,…

Atlas Biotechnologies will fund and provide support to three research projects at the University of Alberta to possibly identify cannabis component(s) that could help people with neurological diseases like multiple sclerosis (MS). The cannabis plant produces hundreds of biological compounds, the best-known being tetrahydrocannabinol (THC) — the psychoactive compound primarily…

Prices for new multiple sclerosis (MS) therapies in the United States are decided most by competitors’ prices, and continual increases in the cost of existing treatments by concerns for company profits and future growth, a study based on”confidential” interviews with four biotech executives with experience in the MS field reports. U.S.

There is a sizable gap between advancements in treatment for multiple sclerosis (MS) and their regulatory approval, which is a circumstance that necessitates increased  advocacy on a global scale. This concern was a major topic of conversation recently at the XXIV World Congress of Neurology (WCN 2019)…

People with multiple sclerosis (MS) tend to have low levels in their blood serum of certain antibodies that can protect against infection, regardless of whether they are using a disease-targeted therapy or not, a study reports. These levels were not so low as to risk infection on their own,…

The transcription factor family AP-1 is crucial for the proper activation of immune T-cells, a new study shows, and this finding may have important implications for autoimmune diseases such as multiple sclerosis. The study, titled “AP-1 activity induced by co-stimulation is required for chromatin opening during…

Metformin, a common diabetes treatment that works to mimic dietary fasting, was seen to promote remyelination in the stem cells of elderly rats, suggesting it may be useful in treating multiple sclerosis. “Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells” was published in…

People with relapsing-remitting multiple sclerosis (RRMS) who don’t use disease-modifying therapies (DMTs) are more likely to have been misdiagnosed previously, and to have poorer relationships with their healthcare providers, the results of a new survey suggest. The survey, titled “Multiple Sclerosis In America 2019,” was conducted by …

ExeGi Pharma announced a new clinical trial testing its probiotic Visbiome in people with multiple sclerosis (MS). The study will further evaluate whether changing bacteria in the gut could be therapeutically beneficial in MS. The human body hosts millions upon millions of bacterial guests, the majority of which…

A new app might make it easier for healthcare providers to assess cognitive function in people with multiple sclerosis (MS). The app was described in the study, “iCAMS: Assessing the Reliability of a BICAMS Tablet Application,” published in the International Journal of MS…

The volume of atrophied (shrunken) regions in the brain, as visible through magnetic resonance imaging (MRI) scans, can predict disease progression in people with multiple sclerosis (MS), new research reveals. The finding was published in the journal Radiology in an article titled, “Atrophied Brain T2 Lesion Volume…

If necessary, women with relapsing multiple sclerosis can continue treatments based on interferon beta while pregnant and breastfeeding, according to an updated recommendation by an office of the European Medicines Agency (EMA). Interferon beta-based treatments are a mainstay of approved MS therapies. Three specific treatments were mentioned in press…

EMD Serono (Merck KGaA in Germany) is opening two pivotal and global Phase 3 clinical trials to evaluate the effectiveness and safety of oral evobrutinib in people with relapsing multiple sclerosis (MS). Evobrutinib, also known as M2951, works by blocking a protein called Bruton’s tyrosine kinase (BTK), which is…

The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol (CBD), cautioning them that making unsubstantiated claims about the health benefits of CBD could lead to legal action. The agency “urges the companies to review all claims made for their…

New guidelines from the American Academy of Neurology (AAN) recommend that people with multiple sclerosis (MS) keep up with regular vaccinations, including annual flu shots, but be sure to first advise their doctor on medications they are using. The guidelines were published in the journal Neurology, in the report…

The first in-human clinical trial of EHP-101, an investigational treatment for multiple sclerosis (MS) and systemic scleroderma (SSc), has been successfully completed, Emerald Health Pharmaceuticals (EHP) announced. EHP-101 demonstrated it was safe and well-tolerated in healthy volunteers, supporting further clinical development of EHP-101 in future Phase 2 clinical trials. The…

Imaging techniques that measure damage to the brain, in addition to those that detect lesions, may be useful in predicting likely disease progression in people with clinically isolated syndrome (CIS), a study found. The study, “Early imaging predictors of longer term multiple sclerosis risk and severity…

The National Health Service (NHS) England announced an initiative that aims to speed diagnoses and ensure better all-around care for people with progressive neurological conditions like multiple sclerosis (MS), Parkinson’s disease, and motor neuron disease (MND). Experts at NHS England, as part of the NHS RightCare…

Medications for treating certain rare and chronic conditions,  including multiple sclerosis (MS), are now available from the specialty and home delivery pharmacy AllianceRx Walgreens Prime, the company announced. The newly included specialty medications are all limited distribution drugs (LDDs), which means the drug manufacturers have signed agreements giving very…